Skip to main content

Advertisement

Springer Nature Link
Log in

Improved identification of core biomarkers and drug repositioning for ovarian cancer: an integrated bioinformatics approach

  • Original Article
  • Published:
Network Modeling Analysis in Health Informatics and Bioinformatics Aims and scope Submit manuscript

Abstract

Ovarian cancer (OC) is a frequent fatal malignancy in female reproductive systems with poor early diagnosis. There are several currently utilized popular methods for the detection of OC biomarkers from the microarray transcriptomics dataset, but these methods suffer from the limitation in the identification of biomarkers in the presence of outlier. In this study, we introduced a rule for modification of outlier to improve the performance of biomarker selection methods. We employed the proposed procedure on simulated and three publicly available ovarian cancer gene expression datasets, and improved performance of the proposed procedure was observed. We identified 226 differentially expressed genes (DEGs) overlapped in 3 proposed modified microarray OC datasets using LIMMA in R. These DEGs were underwent Gene Ontology analysis and revealed apoptotic signaling and programmed cell death as an important biological process. The pathway enrichment analysis showed molecular pathways in OC. We also identified FOXC1, GATA2, E2F1, YY1, and FOXL1 as regulatory transcription factors. The protein–protein interaction analysis demonstrated upregulated hub proteins (HDAC1, RPS15, SF3B1, YWHAH, EIF1AX, CALM1, PSME3, UBC, MCL1, NFE2L2), and down-regulated hub proteins (RPL7, RPL9, HSP90AB1, RPS16, RPL30, SKP1, RPL10, RPL14, RPL24, RPLP1). The differential expression of these hub proteins was cross-validated in independent OC RNA-Seq datasets from the TCGA database. The prognostic performance of these hub proteins was observed associated with the worst survival outcomes in OC. Finally, considering 226 DEGs as gene signature, using the L1000CDS2, we revealed 18 drugs in OC with overlap > 0.04. The predicted drugs were repositioned in OC considering the core biomarker signature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  • Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG, Treviño V (2013) SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 8:1–9. https://doi.org/10.1371/journal.pone.0074250

    Article  Google Scholar 

  • Altinok G, Powell IJ, Che M, Hormont K, Sarkar FH, Sakr WA, Grignon D, Liao DJ (2006) Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. Prostate Cancer Prostatic Dis 9:77–82

    Google Scholar 

  • Asifuzzaman MI, Akter H, Rashid MM, Mollah MNH, Islam SMS, Shahjaman M (2019) Improved k-nearest neighbors approach for incomplete and contaminated gene expression datasets. J Biosci 27:31–41

    Google Scholar 

  • Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M (2012) NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 41:D991–D995

    Google Scholar 

  • Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300

    MathSciNet  MATH  Google Scholar 

  • Bezerra DP, Pessoa C, de Moraes MO, Saker-Neto N, Silveira ER, Costa-Lotufo LV (2013) Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci 48:453–463

    Google Scholar 

  • Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT (2015) Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 34:1341–1353

    Google Scholar 

  • Coburn SB, Bray F, Sherman ME, Trabert B (2017) International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J cancer 140:2451–2460

    Google Scholar 

  • Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J cancer 127:2893–2917

    Google Scholar 

  • Gov E, Kori M, Arga KY (2017) Multiomics analysis of tumor microenvironment reveals Gata2 and miRNA-124-3p as potential novel biomarkers in ovarian cancer. OMICS 21:603–615

    Google Scholar 

  • Grant S, Easley C, Kirkpatrick P (2007) Vorinostat. Nat Rev Drug Discov 6:21–22. https://doi.org/10.1038/nrd2227

    Article  Google Scholar 

  • Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T (2010) Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J cancer 127:1332–1346

    Google Scholar 

  • Hoque ME, Karim S, Siddiqui MMR, Ahmed T (2017) Report on three cases of advance ovarian cancer upon Bangladeshi population: successful management with bevacizumab based chemotherapy. Anwer Khan Mod Med Coll J 8:157–161

    Google Scholar 

  • Huang W, Bhavsar A, Ward RE, Hall JCE, Priestley JV, Michael-Titus AT (2009) Arachidonyl trifluoromethyl ketone is neuroprotective after spinal cord injury. J Neurotrauma 26:1429–1434

    Google Scholar 

  • Islam T, Rahman MR, Shuvo MAH, Shahjaman M, Islam MR, Karim MR (2019) Drug repositioning and biomarkers in low-grade glioma via bioinformatics approach. Informatics Med Unlocked 17:100250

    Google Scholar 

  • Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH (2013) Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J cancer 133:260–265

    Google Scholar 

  • Jurczyszyn A, Zebzda A, Czepiel J, Perucki W, Bazan-Socha S, Cibor D, Owczarek D, Majka M (2014) Geldanamycin and its derivatives inhibit the growth of myeloma cells and reduce the expression of the MET receptor. J Cancer 5:480

    Google Scholar 

  • Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249–257

    Google Scholar 

  • Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583–621

    MATH  Google Scholar 

  • Lepage CC, Nachtigal MW, McManus KJ (2019) Diminished SKP1 or CUL1 expression induces chromosome instability in high-grade serous ovarian cancer precursor cells. Am Assoc Cancer Res. https://doi.org/10.1158/1538-7445.AM2019-1739

    Article  Google Scholar 

  • Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo W-L, Gusberg AH, Whitaker RS (2009) Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 7:210–220

    Google Scholar 

  • Nadon R, Shoemaker J (2002) Statistical issues with microarrays: processing and analysis. TRENDS Genet 18:265–271

    Google Scholar 

  • Rahman MR, Islam T, Gov E, Turanli B, Gulfidan G, Shahjaman M, Banu NA, Mollah MNH, Arga KY, Moni MA (2019) Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis. Medicina (Kaunas). https://doi.org/10.3390/medicina55010020

    Article  Google Scholar 

  • Schmid BC, Oehler MK (2014) New perspectives in ovarian cancer treatment. Maturitas 77:128–136

    Google Scholar 

  • Shahjaman M, Kumar N, Mollah M, Hossain M, Ahmed M, Ara Begum A, Haque N (2017) Robust significance analysis of microarrays by minimum β-divergence method. BioMed Res Int 2017:5310198. https://doi.org/10.1155/2017/5310198

    Article  Google Scholar 

  • Shahjaman M, Rahman MR, Islam SMS, Mollah MNH (2019) A robust approach for identification of cancer biomarkers and candidate drugs. Medicina (Kaunas). https://doi.org/10.3390/medicina55060269

    Article  Google Scholar 

  • Shao A, Wang Z, Wu H, Dong X, Li Y, Tu S, Tang J, Zhao M, Zhang J, Hong Y (2016) Enhancement of autophagy by histone deacetylase inhibitor trichostatin a ameliorates neuronal apoptosis after subarachnoid hemorrhage in rats. Mol Neurobiol 53:18–27

    Google Scholar 

  • Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30

    Google Scholar 

  • Simões-Pereira J, Moura MM, Marques IJ, Rito M, Cabrera RA, Leite V, Cavaco BM (2019) The role of EIF1AX in thyroid cancer tumourigenesis and progression. J Endocrinol Invest 42:313–318

    Google Scholar 

  • Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:1–25. https://doi.org/10.2202/1544-6115.1027

    Article  MathSciNet  MATH  Google Scholar 

  • Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao W-N, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR (2017) A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171:1437–1452.e17. https://doi.org/10.1016/j.cell.2017.10.049

    Article  Google Scholar 

  • Sumanasekera W, Beckmann T, Fuller L, Castle M, Huff M (2018) Epidemiology of ovarian cancer: risk factors and prevention. Biomed J 1:13

    Google Scholar 

  • Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP (2015) STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43:D447–D452

    Google Scholar 

  • Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284–296

    Google Scholar 

  • Turanli B, Karagoz K, Bidkhori G, Sinha R, Gatza ML, Uhlen M, Mardinoglu A, Arga KY (2019a) Multi-omic data interpretation to repurpose subtype specific drug candidates for breast cancer. Front Genet 10:420. https://doi.org/10.3389/fgene.2019.00420

    Article  Google Scholar 

  • Turanli B, Zhang C, Kim W, Benfeitas R, Uhlen M, Arga KY, Mardinoglu A (2019b) Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning. EBioMedicine 42:386–396. https://doi.org/10.1016/j.ebiom.2019.03.009

    Article  Google Scholar 

  • Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 98:5116–5121

    MATH  Google Scholar 

  • Wang B, Liu S-Z, Zheng R-S, Zhang F, Chen W-Q, Sun X-B (2014) Time trends of ovarian cancer incidence in China. Asian Pacific J cancer Prev 15:191–193

    Google Scholar 

  • Wang L, Li L, Yang Z (2016) Correlation of FOXC1 protein with clinicopathological features in serous ovarian tumors. Oncol Lett 11:933–938

    Google Scholar 

  • Wilcoxon F (1945) Individual comparisons by ranking methods. Biom Bull 1(6):80–83

    Google Scholar 

  • Xia J, Gill EE, Hancock REW (2015) NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc 10:823

    Google Scholar 

  • Xiang W, Yang C-Y, Bai L (2018) MCL-1 inhibition in cancer treatment. Onco Targets Ther 11:7301

    Google Scholar 

  • Yu L, Li J-J, Liang X-L, Wu H, Liang Z (2019) PSME3 promotes TGFB1 secretion by pancreatic cancer cells to induce pancreatic stellate cell proliferation. J Cancer 10:2128

    Google Scholar 

  • Zhan L, Zhang Y, Wang W, Song E, Fan Y, Wei B (2016) E2F1: a promising regulator in ovarian carcinoma. Tumor Biol 37:2823–2831

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Statistics, Begum Rokeya University, Rangpur, Bangladesh

    Md Shahjaman, Fatema Tuz Zohora Jui & Sukanta Das

  2. Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, Bangladesh

    Tania Islam & Md Rezanur Rahman

  3. Department of Biochemistry and Biotechnology, School of Biomedical Science, Khwaja Yunus Ali University, Enayetpur, Sirajganj, Bangladesh

    Md Rezanur Rahman

Authors
  1. Md Shahjaman
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Fatema Tuz Zohora Jui
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Tania Islam
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Sukanta Das
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Md Rezanur Rahman
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence to Md Shahjaman or Md Rezanur Rahman.

Ethics declarations

Conflict of interest

Authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 30 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shahjaman, M., Jui, F.T.Z., Islam, T. et al. Improved identification of core biomarkers and drug repositioning for ovarian cancer: an integrated bioinformatics approach. Netw Model Anal Health Inform Bioinforma 9, 62 (2020). https://doi.org/10.1007/s13721-020-00267-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13721-020-00267-2

Keywords